End Points, page-21

@IndexInvestor - "I guess ACW doesn't really want this kind of publicity pre-results"

Dr Bill Ketelbey and Actinogen Medical have been retweeted the Sunrise story on Twitter as well as on the Facebook since this morning.

Tweeter 1 - Dr Bill Ketelbey Retweeted
Sunrise‏Verified account @sunriseon79h9 hours ago

Researchers could be on the brink of a revolutionary treatment that reverses the effects of Alzheimer's disease!

Tweeter 2 : Actinogen Medical‏ @ActinogenMed4h4 hours ago

Actinogen Medical Retweeted Sunrise

#Xanamem works by targeting & lowering cortisol, the hormone the body processes under stress. In 2016, @ActinogenMed initiated XanADu, a Ph II Safety, Tolerability & Efficacy trial of Xanamem in patients with mild #Alzheimers. Results are expected in less than 3 months from now.

Tweeter 3 - WE Buchan IR‏ @BuchanIR2h2 hours ago

Wonderful to see our client @ActinogenMed's Phase II XanADu trial featured on @7NewsSydney highlighting their important work in helping patients with Alzheimer's

Facebook -

Actinogen Medical

3 hrs ·

#Xanamem works by targeting and lowering #cortisol, the hormone the body processes under #stress. In 2016, Actinogen Medical initiated XanADu, a Ph II, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability and Efficacy of 10mg daily Xanamem in patients with mild Alzheimer’s disease. Patient recruitment and treatment commenced in mid-2017 and was completed in 2018 with 186 patients randomised across 25 sites in Australia, UK and USA. Results are expected in less than 3 months from now.

#clinicaltrials#Actinogen#stressawarenessmonth#Alzheimersdisease